CURE Global X S&P Biotech ETF
- 47.770
- 0.0000.00%
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
Amgen Options Trading: A Deep Dive Into Market Sentiment
Smart Money Is Betting Big In ABBV Options
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
Eurozone Stock Gains Are Priced in – Time to Return to US's Reign
Wells Fargo Sees Opportunities in MidCaps – Here Are SA's Top Quant-rated
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
BlackRock Sees 'Bright Spots' in Global Stocks Amid Narrowing U.S. Outperformance Gap
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Notable Healthcare Headlines for the Week: Pfizer, Sanofi, Sarepta Therapeutics and Medtronic in Focus
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
Is AbbVie Gaining or Losing Market Support?
Top 10 S&P 500 Performers of 2025 All Returned Over 20% as the Broader Index Struggles
Democrats Warn Trump About Consequences of HIV Prevention Cuts
10 Health Care Stocks Whale Activity In Today's Session
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps